

LW0303F

HeLa-EGF Lysate

Whole lysate from HeLa cell lysate that were cultivated to 70-90% confluency and deprived of serum for 18-20 hours and then treated for 100 ng/ml epidermal growth factor (EGF) for 10 minutes prior to harvesting



KINEXUS

Address: 8755 Ash Street, Suite 1
Vancouver, British Columbia,
Canada V6P 6T3

Email: info@kinexus.ca
Phone: 604-323-2547

Production

Product Name Long:	Human epidermoid carcinoma HeLa cells - EGF-treated - Whole lysate
Production Method:	HeLa cell lysates were cultivated to 70-90% confluency and deprived of serum for 18-20 hours and then treated for 100 ng/ml epidermal growth factor (EGF) for 10 minutes prior to harvesting. Lysates were prepared from scrapped cells that were homogenized by sonication in buffer formulated with 1% Triton X-100, 60 mM β -glycerophosphate, pH 7.2, 20 mM MOPS, 20 mM sodium pyrophosphate, 30 mM sodium fluoride, 5 mM EDTA, 3 mM benzamidine, 2 mM EGTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonylfluoride, 1 mM dithiothreitol, 10 μ M leupeptin, and 5 μ M pepstatin A. Lysates were prepared following sonication and 30 min ultracentrifugation at 100,000 rpm. Lysates were further diluted in homogenizing buffer at a final concentration of 3 mg/ml.
Amount:	200 μ g
Protein Concentration:	3 mg/ml
Storage Stability:	1 year at -70°C

Applications

Lysate Use Description:	For testing antibodies by immunoprecipitation or immunoblotting, and for assays of enzymes.
--------------------------------	---

This product is for in vitro research use only and is not intended for use in humans or animals.

For more information on our products please visit www.kinexusproducts.ca or contact us at 1-888-546-3987